BOSTON (EGMN) - Morphine is a poor candidate for transdermal drug delivery, Judith Paice, Ph.D., said at the annual meeting of the American Academy of Hospice and Palliative Medicine.Dr. Paice said she and her colleagues conducted a small study to assess the bioavailability of a topical formulation of morphine relative to the 100% bioavailable subcutaneous dose, but in blood samples collected from the participants beginning 5 minutes to 10 hours after dose administration "we seldom detected morphine...